Cytokinetics inc (CYTK)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Research and development, milestone, grant and other revenues, net

-

-

-

-

-

-

-

-

-

-

5,862

-1,889

2,707

34,219

6,014

3,852

151

14,713

27

0

0

3,377

4,761

4,196

5,232

4,113

2,495

446

493

1,241

751

746

644

740

433

399

374

88

-

Total revenues

3,825

5,212

6,055

7,137

8,464

9,377

10,641

6,215

5,268

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development revenues from related parties, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,296

-

3,786

3,510

2,791

16,110

1,920

843

665

564

564

563

328

943

963

1,095

1,176

17

994

654

389

306

462

License revenues from related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,974

-

4,132

3,032

1,623

0

0

0

0

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Total revenues

-

-

-

-

-

-

-

-

-

-

6,180

3,053

4,153

33,137

59,047

5,802

8,421

9,757

7,945

6,542

4,414

21,758

9,415

7,788

7,979

24,349

4,469

1,009

821

2,184

1,714

1,841

1,820

757

1,427

1,053

763

394

462

Operating expenses:
Research and development

21,738

18,334

20,229

24,017

23,545

24,027

21,391

21,582

22,135

26,251

24,947

19,809

19,289

18,775

17,865

9,723

13,534

13,249

11,557

12,636

8,956

8,779

11,420

11,737

12,490

13,824

13,445

12,347

9,834

9,858

8,798

8,242

8,745

8,599

8,891

10,513

9,179

9,547

10,236

General and administrative

12,449

10,584

9,753

9,836

9,437

6,808

7,164

8,046

9,264

10,258

9,657

8,438

8,115

6,675

7,217

7,090

6,841

5,529

5,276

4,495

4,367

4,558

3,993

4,458

4,259

4,093

3,635

3,730

3,634

3,814

2,991

2,568

3,056

2,863

3,204

4,187

3,336

3,412

3,380

Total operating expenses

34,187

28,918

29,982

33,853

32,982

30,835

28,555

29,628

31,399

36,509

34,604

28,247

27,404

25,450

25,082

16,813

20,375

18,778

16,833

17,131

13,323

13,337

15,413

16,195

16,749

17,917

17,080

16,077

13,468

13,672

11,787

10,797

11,760

12,654

12,095

14,700

12,515

12,959

13,616

Restructuring reversals

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-2

-13

-41

-

0

-

-

-

-

Operating loss

-30,362

-23,706

-23,927

-26,716

-24,518

-21,458

-17,914

-23,413

-26,131

-36,527

-28,424

-25,194

-23,251

7,687

33,965

-11,011

-11,954

-9,021

-8,888

-10,589

-8,909

8,421

-5,998

-8,407

-8,770

6,432

-12,611

-15,068

-12,647

-11,488

-10,073

-8,956

-9,940

-11,897

-10,668

-13,647

-11,752

-12,565

-13,154

Interest expense

4,077

2,731

1,345

1,377

1,170

1,169

867

898

863

683

806

782

745

714

714

707

563

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on liability related to the sale of future royalties

5,689

5,533

5,321

5,064

4,819

4,741

4,559

4,338

4,129

4,050

3,906

3,717

2,307

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest and other income, net

723

1,330

1,020

1,044

1,141

900

1,323

1,126

842

775

779

612

436

184

111

107

62

60

39

38

37

22

27

33

26

99

23

27

28

33

29

13

12

20

29

15

40

48

10

Net (loss) income before income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

33,362

-

-12,455

-

-8,849

-10,551

-8,872

8,443

-5,971

-8,374

-8,744

6,531

-12,588

-15,041

-12,619

-11,455

-10,044

-8,943

-9,928

-11,877

-10,639

-13,632

-11,712

-12,517

-13,144

Income tax benefit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

-

0

0

0

0

0

0

0

0

0

0

0

-

-

-

-

-

0

-

-

-176

-

Net loss

-39,405

-30,640

-29,573

-32,113

-29,366

-26,468

-22,017

-27,523

-30,281

-40,485

-32,357

-29,081

-25,867

7,157

33,362

-11,611

-12,455

-9,229

-8,849

-10,551

-8,872

8,443

-5,971

-8,374

-8,744

6,531

-12,588

-15,041

-12,619

-11,455

-10,044

-8,943

-9,928

-11,877

-10,639

-13,632

-11,712

-12,341

-13,144

Net (loss) income per share basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.84

-

-

-

-0.23

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income per share diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.77

-

-

-

-0.23

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average number of shares used in computing net (loss) income per share basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

39,926

-

-

-

38,752

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average number of shares used in computing net (loss) income per share diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

43,217

-

-

-

38,752

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividend related to beneficial conversion feature of convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,307

-

-

0

2,857

-

-

-

Net loss allocable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-11,455

-10,044

-10,250

-9,928

-11,877

-10,639

-16,489

-11,712

-12,341

-13,144

Net loss per share — basic and diluted

-0.66

-0.51

-0.50

-0.56

-0.54

-0.48

-0.40

-0.51

-0.56

-0.77

-0.60

-0.60

-0.62

-

-

-0.29

-0.31

-

-

-0.27

-0.23

-

-0.16

-0.23

-0.27

0.30

-0.43

-0.58

-0.53

-0.96

-0.45

-0.76

-0.13

-3.74

-0.15

-0.23

-0.18

-0.19

-0.21

Weighted-average number of shares used in computing net loss per share — basic and diluted

59

113,957

58,640

57,648

54

54,699

54,626

54,293

54,062

54,101

53,719

48,218

41,578

-

-

39,666

39,592

-

-

38,725

38,675

-

36,609

36,443

32,985

29,922

29,395

25,773

24,010

-39,552

22,360

13,538

76,082

-

72,280

71,151

-

-

-

Other comprehensive income:
Unrealized gain on available-for-sale securities, net

934

-40

-42

155

106

53

-3

-39

146

-83

512

-78

-145

-115

23

73

7

134

2

18

-1

-28

11

0

6

-12

19

-10

-8

-

-

-

-

-

-

-

-

-

-

Weighted-average number of shares used in computing net loss per common share - basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

66,911

64,434

63,815

Comprehensive loss

-38,471

-30,680

-29,615

-31,958

-29,260

-26,415

-22,020

-27,562

-30,135

-40,568

-31,845

-29,159

-26,012

7,042

33,385

-11,538

-12,448

-9,095

-8,847

-10,533

-8,873

8,415

-5,960

-8,374

-8,738

6,519

-12,569

-15,051

-12,627

-11,450

-10,030

-8,942

-9,933

-11,882

-10,646

-13,626

-11,699

-

-

Research and Development Revenues [Member]
Total revenues

3,825

5,212

6,055

7,137

8,464

9,377

8,726

4,680

3,585

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

License Revenues [Member]
Total revenues

-

-

0

0

-

0

1,915

1,535

1,683

2,093

318

4,942

1,446

-

53,033

1,950

-

-

-

-

-

2,271

2,734

2,749

2,082

-

1,410

-

-

-

-

-

-

-

-

-

-

-

-